butylparaben profile

ID Source	ID
PubMed CID	7184
CHEMBL ID	459008
CHEBI ID	88542
SCHEMBL ID	3647
MeSH ID	M0114834

Synonym
BIDD:ER0231
butyl-p-hydroxybenzoate
MLS002154054
BRD-K08287586-001-03-6
4-hydroxybenzoic acid, butyl ester
butylparaben
butyl 4-hydroxybenzoate
butyl-parasept
butyl tegosept
n-butyl p-hydroxybenzoate
SPF ,
butyl paraben
preserval b
butyl p-hydroxybenzoate
solbrol b
butyl butex
nipabutyl
p-hydroxybenzoic acid, butyl ester
butyl chemosept
aseptoform butyl
butoben
butyl parasept
wln: qr dvo4
tegosept b
4-(butoxycarbonyl)phenol
tegosept butyl
p-hydroxybenzoic butyl ester
nsc-8475
nsc8475
94-26-8
benzoic acid, 4-hydroxy-, butyl ester
nsc-13164
inchi=1/c11h14o3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12h,2-3,8h2,1h
NCGC00016354-01
cas-94-26-8
BSPBIO_000708
PRESTWICK3_000894
PRESTWICK2_000894
BPBIO1_000780
NCGC00091142-01
n-butyl-p-hydroxybenzoate
MLS000575004
smr000462402
AB00513951
brn 1103741
n-butyl paraben
epa pesticide chemical code 061205
hsdb 286
ai3-02930
fema number 2203
benzoic acid, p-hydroxy-, butyl ester
nsc 8475
4-hydroxybenzoic acid butyl ester
butyl parahydroxybenzoate
einecs 202-318-7
n-butyl parahydroxybenzoate
ccris 2462
p-hydroxybenzoic acid n-butyl ester
fema no. 2203
butyl par asept
butylparaben [usan]
p-hydroxy butyl benzoate
p-hydroxybenzoic acid butyl ester
n-butyl hydroxybenzoate
caswell no. 130a
butyl 4-hydroxybenzoate, >=99%
butylparaben (nf)
butylparaben (tn)
butyl parahydroxybenzoate (jp17)
butyl parahydroxybenzoate (tn)
D01420
NCGC00091142-02
PRESTWICK1_000894
SPBIO_002917
PRESTWICK0_000894
n-butyl 4-hydroxybenzoate
cid_7184
bdbm23448
butyl 4-hydroxybenzoate, >=99.0% (gc)
HMS2094A21
MLS002303045
H0210
HMS1570D10
CHEMBL459008
chebi:88542 ,
butyl p-hydroxy benzoate
NCGC00016354-03
AKOS000121421
A844895
HMS2097D10
tox21_300332
NCGC00254294-01
NCGC00259334-01
tox21_201785
B3771
nsc-759303
nsc759303
pharmakon1600-01505995
dtxcid90209
tox21_110393
dtxsid3020209 ,
HMS2220G15
S4584
NCGC00016354-02
NCGC00016354-07
NCGC00016354-05
NCGC00016354-06
NCGC00016354-04
unii-3qpi1u3fv8
butylparaben [nf]
3qpi1u3fv8 ,
F0266-0124
FT-0623315
27K ,
HMS3327P04
butyl parahydroxybenzoate [ep monograph]
butylparaben [hsdb]
butylparaben [usp-rs]
butylparaben [ii]
butyl parahydroxybenzoate [jan]
butyl hydroxybenzoate [mart.]
propyl hydroxybenzoate impurity d [ep impurity]
butyl hydroxybenzoate [who-dd]
butylparaben [vandf]
methyl parahydroxybenzoate impurity d [ep impurity]
butylparaben [inci]
butyl p-hydroxy benzoate [fhfi]
butyl parahydroxybenzoate [ep impurity]
butylparaben [mi]
CCG-213596
SCHEMBL3647
NCGC00016354-11
tox21_110393_1
CS-4783
W-100204
AC-34535
n-butyl-paraben
p-hydroxybenzoic acid, n-butyl ester
n-butyl-4-hydroxybenzoate
lexgard b
HY-B1431
AB00513951_09
4MG9
SR-01000389296-3
mfcd00016478
Z291799028
sr-01000389296
SR-01000389296-1
butyl 4-hydroxybenzoate, saj first grade, >=99.0%
4-hydroxybenzoic acid-n-butyl ester
butyl parahydroxybenzoate (jp15)
butyl //p//-hydroxybenzoate
fema 2203
SBI-0206946.P001
HMS3714D10
Q3302873
DB14084
n-butyl-p-hydroxybenzoate,(s)
4-hydroxybenzoic acid-n-butyl ester 1000 microg/ml in acetonitrile
AS-14309
BRD-K08287586-001-08-5
A16382
EN300-21566
butyl-paraben
butyl 4-hydroxybenzoate (butyl paraben)
SY032891

Excerpt	Reference
"Butylparaben is an organic compound that is used as an antimicrobial preservative in cosmetics and can cause neurotoxicity. "	( Hyun, SA; Jang, S; Ka, M; Ko, MY; Lee, BS; Rho, J; Seo, JW, 2022)
"Butylparaben is an ubiquitous environmental endocrine disruptor, that is commonly used in cosmetics and personal care product due to its anti-microbial properties. "	( Gao, Y; Ma, H; Sun, L; Xue, Y; Zhang, D; Zhang, M; Zhang, Y, 2023)
"Butylparaben (BP) is an antimicrobial agent utilized for decades as a preservative in numerous consumer products. "	( Blystone, CR; Brix, A; Cunny, H; Hubbard, TD; McBride, S; McIntyre, BS; Roberts, GK; Shockley, K; Turner, KJ; Waidyanatha, S, 2020)

Excerpt	Reference
"Butylparaben has been shown to cause developmental toxicity, endocrine and metabolic disorders and immune diseases."	( Gao, Y; Ma, H; Sun, L; Xue, Y; Zhang, D; Zhang, M; Zhang, Y, 2023)
"Butylparaben has estrogenic and antiandrogenic properties and is known to reduce sperm counts in rats following perinatal exposure."	( Axelstad, M; Boberg, J; Christiansen, S; Hass, U; Mandrup, K; Svingen, T; Vinggaard, AM, 2016)

Excerpt	Reference
"Butylparaben displays dose-dependent systemic exposure up to the maximum dose of 50 mg/kg/day and repeated administration of butylparaben for 13 weeks shows no bioaccumulation."	( Bae, JS; Choi, YK; Kim, KB; Lee, BM; Lee, JD; Shin, CY; Shin, HC; Song, SW, 2021)

Class	Description
organic molecular entity	Any molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	53.5180	0.0072	15.7588	89.3584	AID1224835; AID588342; AID624030
acetylcholinesterase	Homo sapiens (human)	Potency	36.0390	0.0025	41.7960	15,848.9004	AID1347398
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	8.8936	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
ATAD5 protein, partial	Homo sapiens (human)	Potency	23.1093	0.0041	10.8903	31.5287	AID504467
GLI family zinc finger 3	Homo sapiens (human)	Potency	55.1482	0.0007	14.5928	83.7951	AID1259369
AR protein	Homo sapiens (human)	Potency	28.6026	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID588515; AID743035; AID743042; AID743054; AID743063
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	0.1259	0.0013	18.0743	39.8107	AID926; AID938
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	15.0035	0.0006	57.9133	22,387.1992	AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	32.8221	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	27.1829	0.0004	17.9460	75.1148	AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	17.3768	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	1.9494	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	11.9059	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	14.9873	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	0.0010	0.3758	27.4851	61.6524	AID588527
pregnane X nuclear receptor	Homo sapiens (human)	Potency	62.7119	0.0054	28.0263	1,258.9301	AID1346982; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	24.9145	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID1259383; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	21.8761	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	29.4556	0.0010	19.4141	70.9645	AID588537; AID743191
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	22.9752	0.0007	23.0674	1,258.9301	AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	5.2857	0.0017	23.8393	78.1014	AID743083
activating transcription factor 6	Homo sapiens (human)	Potency	62.4149	0.1434	27.6121	59.8106	AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	55.6274	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	62.4149	0.0578	21.1097	61.2679	AID1159526
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	12.5893	0.0020	7.5337	39.8107	AID891
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	6.3096	0.0025	5.8400	31.6228	AID899
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	0.0011	0.0100	39.5371	1,122.0200	AID588545
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	7.8135	0.0003	23.4451	159.6830	AID743065; AID743067
histone deacetylase 9 isoform 3	Homo sapiens (human)	Potency	29.4933	0.0376	17.0823	61.1927	AID1259364; AID1259388
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	39.8107	0.0398	16.7842	39.8107	AID1454
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	32.7631	0.0006	27.2152	1,122.0200	AID651741; AID720636; AID743219
geminin	Homo sapiens (human)	Potency	13.3359	0.0046	11.3741	33.4983	AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	32.1968	0.0056	12.3677	36.1254	AID624032
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	2.5119	0.1259	12.2344	35.4813	AID1458
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	31.6228	0.0200	10.7869	31.6228	AID912
lamin isoform A-delta10	Homo sapiens (human)	Potency	20.5524	0.8913	12.0676	28.1838	AID1487
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	14.5192	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	24.5454	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	71.4844	0.0023	19.5956	74.0614	AID651631; AID720552
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	14.5192	0.0015	51.7393	15,848.9004	AID1259244
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	10.5909	0.0266	22.4482	66.8242	AID651802
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	7.0795	1.9953	25.5327	50.1187	AID624287
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	47.9322	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	48.7364	0.0119	12.2221	68.7989	AID651632
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Estrogen receptor	Homo sapiens (human)	IC50 (µMol)	1.4200	0.0000	0.7237	32.7000	AID1505260
Oxysterols receptor LXR-beta	Homo sapiens (human)	Ki	66.0000	0.0022	0.0730	0.3520	AID1562690
2-5A-dependent ribonuclease	Homo sapiens (human)	IC50 (µMol)	2,400.0000	1.3200	1.4325	1.6300	AID1820767
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glycogen synthase kinase-3 beta isoform 1	Homo sapiens (human)	EC50 (µMol)	300.0000	0.2125	22.1562	83.9400	AID434954
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
antral ovarian follicle growth	Estrogen receptor	Homo sapiens (human)
epithelial cell development	Estrogen receptor	Homo sapiens (human)
chromatin remodeling	Estrogen receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
signal transduction	Estrogen receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Estrogen receptor	Homo sapiens (human)
androgen metabolic process	Estrogen receptor	Homo sapiens (human)
male gonad development	Estrogen receptor	Homo sapiens (human)
negative regulation of gene expression	Estrogen receptor	Homo sapiens (human)
positive regulation of phospholipase C activity	Estrogen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
response to estradiol	Estrogen receptor	Homo sapiens (human)
regulation of toll-like receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic process	Estrogen receptor	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Estrogen receptor	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
response to estrogen	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
stem cell differentiation	Estrogen receptor	Homo sapiens (human)
regulation of inflammatory response	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
RNA polymerase II preinitiation complex assembly	Estrogen receptor	Homo sapiens (human)
uterus development	Estrogen receptor	Homo sapiens (human)
vagina development	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord elongation	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	Estrogen receptor	Homo sapiens (human)
regulation of branching involved in prostate gland morphogenesis	Estrogen receptor	Homo sapiens (human)
mammary gland branching involved in pregnancy	Estrogen receptor	Homo sapiens (human)
mammary gland alveolus development	Estrogen receptor	Homo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongation	Estrogen receptor	Homo sapiens (human)
protein localization to chromatin	Estrogen receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of miRNA transcription	Estrogen receptor	Homo sapiens (human)
regulation of epithelial cell apoptotic process	Estrogen receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of glucose metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of steroid metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor ROR-gamma	Homo sapiens (human)
circadian regulation of gene expression	Nuclear receptor ROR-gamma	Homo sapiens (human)
cellular response to sterol	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of circadian rhythm	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of fat cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor ROR-gamma	Homo sapiens (human)
adipose tissue development	Nuclear receptor ROR-gamma	Homo sapiens (human)
T-helper 17 cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
hormone-mediated signaling pathway	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of triglyceride biosynthetic process	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of cholesterol efflux	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of lipid storage	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of cholesterol storage	Oxysterols receptor LXR-beta	Homo sapiens (human)
intracellular receptor signaling pathway	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of lipid transport	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of cholesterol transport	Oxysterols receptor LXR-beta	Homo sapiens (human)
phosphatidylcholine acyl-chain remodeling	Oxysterols receptor LXR-beta	Homo sapiens (human)
cholesterol homeostasis	Oxysterols receptor LXR-beta	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of fatty acid biosynthetic process	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of proteolysis	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of DNA-templated transcription	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of DNA-templated transcription	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of pinocytosis	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of lipoprotein lipase activity	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of protein metabolic process	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathway	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of high-density lipoprotein particle assembly	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of pancreatic juice secretion	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of secretion of lysosomal enzymes	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Oxysterols receptor LXR-beta	Homo sapiens (human)
positive regulation of miRNA transcription	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of response to endoplasmic reticulum stress	Oxysterols receptor LXR-beta	Homo sapiens (human)
cell differentiation	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Oxysterols receptor LXR-beta	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
rRNA processing	2-5A-dependent ribonuclease	Homo sapiens (human)
mRNA processing	2-5A-dependent ribonuclease	Homo sapiens (human)
protein phosphorylation	2-5A-dependent ribonuclease	Homo sapiens (human)
regulation of mRNA stability	2-5A-dependent ribonuclease	Homo sapiens (human)
negative regulation of viral genome replication	2-5A-dependent ribonuclease	Homo sapiens (human)
fat cell differentiation	2-5A-dependent ribonuclease	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	2-5A-dependent ribonuclease	Homo sapiens (human)
positive regulation of glucose import	2-5A-dependent ribonuclease	Homo sapiens (human)
defense response to virus	2-5A-dependent ribonuclease	Homo sapiens (human)
RNA processing	2-5A-dependent ribonuclease	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
TFIIB-class transcription factor binding	Estrogen receptor	Homo sapiens (human)
transcription coregulator binding	Estrogen receptor	Homo sapiens (human)
transcription corepressor binding	Estrogen receptor	Homo sapiens (human)
transcription coactivator binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
chromatin binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor	Homo sapiens (human)
steroid binding	Estrogen receptor	Homo sapiens (human)
protein binding	Estrogen receptor	Homo sapiens (human)
calmodulin binding	Estrogen receptor	Homo sapiens (human)
beta-catenin binding	Estrogen receptor	Homo sapiens (human)
zinc ion binding	Estrogen receptor	Homo sapiens (human)
TBP-class protein binding	Estrogen receptor	Homo sapiens (human)
enzyme binding	Estrogen receptor	Homo sapiens (human)
protein kinase binding	Estrogen receptor	Homo sapiens (human)
nitric-oxide synthase regulator activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor binding	Estrogen receptor	Homo sapiens (human)
estrogen response element binding	Estrogen receptor	Homo sapiens (human)
identical protein binding	Estrogen receptor	Homo sapiens (human)
ATPase binding	Estrogen receptor	Homo sapiens (human)
14-3-3 protein binding	Estrogen receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Estrogen receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Oxysterols receptor LXR-beta	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Oxysterols receptor LXR-beta	Homo sapiens (human)
DNA binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
protein binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
zinc ion binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
chromatin DNA binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
apolipoprotein A-I receptor binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
nuclear retinoid X receptor binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
ATPase binding	Oxysterols receptor LXR-beta	Homo sapiens (human)
nuclear receptor activity	Oxysterols receptor LXR-beta	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
RNA binding	2-5A-dependent ribonuclease	Homo sapiens (human)
RNA endonuclease activity	2-5A-dependent ribonuclease	Homo sapiens (human)
RNA nuclease activity	2-5A-dependent ribonuclease	Homo sapiens (human)
protein kinase activity	2-5A-dependent ribonuclease	Homo sapiens (human)
protein binding	2-5A-dependent ribonuclease	Homo sapiens (human)
ATP binding	2-5A-dependent ribonuclease	Homo sapiens (human)
rRNA binding	2-5A-dependent ribonuclease	Homo sapiens (human)
ribonucleoprotein complex binding	2-5A-dependent ribonuclease	Homo sapiens (human)
metal ion binding	2-5A-dependent ribonuclease	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleus	Estrogen receptor	Homo sapiens (human)
nucleoplasm	Estrogen receptor	Homo sapiens (human)
transcription regulator complex	Estrogen receptor	Homo sapiens (human)
cytoplasm	Estrogen receptor	Homo sapiens (human)
Golgi apparatus	Estrogen receptor	Homo sapiens (human)
cytosol	Estrogen receptor	Homo sapiens (human)
plasma membrane	Estrogen receptor	Homo sapiens (human)
membrane	Estrogen receptor	Homo sapiens (human)
chromatin	Estrogen receptor	Homo sapiens (human)
euchromatin	Estrogen receptor	Homo sapiens (human)
protein-containing complex	Estrogen receptor	Homo sapiens (human)
nucleus	Estrogen receptor	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Oxysterols receptor LXR-beta	Homo sapiens (human)
nucleoplasm	Oxysterols receptor LXR-beta	Homo sapiens (human)
cytoplasm	Oxysterols receptor LXR-beta	Homo sapiens (human)
cytosol	Oxysterols receptor LXR-beta	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Oxysterols receptor LXR-beta	Homo sapiens (human)
chromatin	Oxysterols receptor LXR-beta	Homo sapiens (human)
nucleus	Oxysterols receptor LXR-beta	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular_component	2-5A-dependent ribonuclease	Homo sapiens (human)
mitochondrial matrix	2-5A-dependent ribonuclease	Homo sapiens (human)
cytosol	2-5A-dependent ribonuclease	Homo sapiens (human)
nuclear matrix	2-5A-dependent ribonuclease	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (68)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1278147	Antiparasitic activity against trypomastigote stage of Trypanosoma cruzi Y assessed as parasite viability after 24 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1820768	Inhibition of recombinant full length H-RNAase L (1 to 741 residues) expressed in Escherichia coli BL21 (DE3) using 5'-FAM-UAA-UCA-AAU-UCU-UAU-UUG-CCC-CAU-UUU-UUU-GGU-UUA-BHQ-1-3' as substrate incubated for 60 min by FRET assay	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID1278150	Antiparasitic activity against amastigote stage of Leishmania infantum infected in BALB/c mouse peritoneal macrophages assessed as reduction of parasite burden after 120 hrs by Giemsa staining-based light microscopic analysis	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1562690	Binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) assessed as inhibitory constant incubated for 30 mins by fluorescence polarization binding assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID1278153	Selectivity index, ratio of CC50 for mouse NCTC-292 cells to IC50 for Trypanosoma cruzi Y amastigotes	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1278151	Cytotoxicity against mouse NCTC-929 cells assessed as cell viability after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1505256	Xenoestrogen activity in human MCF7 cells assessed as stimulation of cell proliferation at 0.125 to 128 ug/ml incubated for 24 hrs by MTT assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Disconnecting the Estrogen Receptor Binding Properties and Antimicrobial Properties of Parabens through 3,5-Substitution.
AID1505254	Antibacterial activity against Staphylococcus aureus 155554A incubated for 16 hrs by microdilution assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Disconnecting the Estrogen Receptor Binding Properties and Antimicrobial Properties of Parabens through 3,5-Substitution.
AID1505259	Xenoestrogen activity in human MCF7 cells assessed as stimulation of estrogen production at 0.125 to 128 ug/ml incubated for 24 hrs by ELISA	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Disconnecting the Estrogen Receptor Binding Properties and Antimicrobial Properties of Parabens through 3,5-Substitution.
AID1820767	Inhibition of recombinant full length H-RNAase L (1 to 741 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate in presence of 2-5A and ATP/MgCl2 by STD-NMR spectroscopy	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID1505260	Displacement of Fluor.ES2 Green from human ERalpha by TR-FRET competitive binding assay	2018	ACS medicinal chemistry letters, Jan-11, Volume: 9, Issue:1	Disconnecting the Estrogen Receptor Binding Properties and Antimicrobial Properties of Parabens through 3,5-Substitution.
AID1562692	Competitive binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) at 1 mM incubated for 30 mins by fluorescence polarization binding assay relative to tracer 1	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID1278149	Antiparasitic activity against promastigote stage of Leishmania infantum assessed as parasite viability after 24 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1278148	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID346025	Binding affinity to beta cyclodextrin	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1309215	Anti-allergic activity in RBL2H3 cells assessed as inhibition of anti-DNP-IgE-induced degranulation at 30 to 300 uM incubated for 20 mins followed by DNP-labeled human serum albumin addition measured after 1 hr by beta-hexosaminidase release assay	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Structure-activity relationships of vanillic acid ester analogs in inhibitory effect of antigen-mediated degranulation in rat basophilic leukemia RBL-2H3 cells.
AID1820766	Inhibition of recombinant full length P-RNAase L (1 to 743 residues)expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate in presence of 2-5A AND ATP/MgCl2 by STD-NMR spectroscopy	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2014	Environmental health perspectives, Dec, Volume: 122, Issue:12	Structural and functional profiling of environmental ligands for estrogen receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	8 (4.28)	18.7374
1990's	16 (8.56)	18.2507
2000's	35 (18.72)	29.6817
2010's	88 (47.06)	24.3611
2020's	40 (21.39)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (0.52%)	5.53%
Reviews	1 (0.52%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	191 (98.96%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
4-hydroxybenzyl alcohol	[no description available]	medium	1	0	benzyl alcohols; phenols	plant metabolite
4-hydroxybenzaldehyde	[no description available]	medium	1	0	hydroxybenzaldehyde	EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor; mouse metabolite; plant metabolite
4-hydroxybenzoic acid	[no description available]	medium	12	0	monohydroxybenzoic acid	algal metabolite; plant metabolite
ethylene glycol	[no description available]	medium	1	0	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin
acetaldehyde	[no description available]	medium	1	0	aldehyde	carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent
acetone	[no description available]	medium	1	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
benzaldehyde	[no description available]	medium	2	0	benzaldehydes	EC 3.1.1.3 (triacylglycerol lipase) inhibitor; EC 3.5.5.1 (nitrilase) inhibitor; flavouring agent; fragrance; odorant receptor agonist; plant metabolite
benzene	[no description available]	medium	1	0	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
benzoic acid	[no description available]	medium	1	0	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
benzyl alcohol	[no description available]	medium	2	0	benzyl alcohols	antioxidant; fragrance; metabolite; solvent
1-butanol	[no description available]	medium	1	0	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
3-cresol	[no description available]	medium	1	0	cresol	human xenobiotic metabolite
dibenzofuran	[no description available]	medium	1	0	dibenzofurans; mancude organic heterotricyclic parent; polycyclic heteroarene	xenobiotic
hydroquinone	[no description available]	medium	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
methanol	[no description available]	medium	1	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
acetanilide	[no description available]	medium	1	0	acetamides; anilide	analgesic
n,n-dimethylaniline	[no description available]	medium	1	0	dimethylaniline; tertiary amine
1-octanol	[no description available]	medium	1	0	octanol; primary alcohol	antifungal agent; bacterial metabolite; fuel additive; kairomone; plant metabolite
4-nitrophenol	[no description available]	medium	1	0	4-nitrophenols	human xenobiotic metabolite; mouse metabolite
phenol	[no description available]	medium	3	0	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
phenylacetic acid	[no description available]	medium	1	0	benzenes; monocarboxylic acid; phenylacetic acids	allergen; Aspergillus metabolite; auxin; EC 6.4.1.1 (pyruvate carboxylase) inhibitor; Escherichia coli metabolite; human metabolite; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite; toxin
1-propanol	[no description available]	medium	1	0	propan-1-ols; short-chain primary fatty alcohol	metabolite; protic solvent
toluene	[no description available]	medium	1	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
acetohexamide	[no description available]	medium	1	0	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
amobarbital	[no description available]	medium	1	0	barbiturates
barbital	[no description available]	medium	1	0	barbiturates	drug allergen
bendroflumethiazide	[no description available]	medium	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzocaine	[no description available]	medium	2	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
butamben	[no description available]	medium	2	0	amino acid ester; benzoate ester; primary amino compound; substituted aniline	local anaesthetic
4-cresol	[no description available]	medium	1	0	cresol	Escherichia coli metabolite; human metabolite; uremic toxin
diazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
dibenzothiophene	[no description available]	medium	1	0	dibenzothiophenes; mancude organic heterotricyclic parent	keratolytic drug
fenbufen	[no description available]	medium	1	0	4-oxo monocarboxylic acid; biphenyls	non-steroidal anti-inflammatory drug
fludiazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; organochlorine compound; organofluorine compound	anxiolytic drug
flufenamic acid	[no description available]	medium	1	0	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flurbiprofen	[no description available]	medium	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
furosemide	[no description available]	medium	1	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
hexobarbital	[no description available]	medium	1	0	barbiturates
hydrochlorothiazide	[no description available]	medium	1	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
2-propanol	[no description available]	medium	1	0	secondary alcohol; secondary fatty alcohol	protic solvent
ketoprofen	[no description available]	medium	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
meclofenamic acid	[no description available]	medium	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
medazepam	[no description available]	medium	1	0	organic molecular entity
mefenamic acid	[no description available]	medium	1	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
vitamin k 3	[no description available]	medium	1	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
fenamic acid	[no description available]	medium	1	0	aminobenzoic acid; secondary amino compound	membrane transport modulator
nimetazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; GABA modulator; sedative
nitrazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
4-chlorophenol	[no description available]	medium	2	0	monochlorophenol
pentobarbital	[no description available]	medium	1	0	barbiturates	GABAA receptor agonist
phenazine	[no description available]	medium	1	0	azaarene; heteranthrene; mancude organic heterotricyclic parent; phenazines; polycyclic heteroarene
phenobarbital	[no description available]	medium	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
sulfadiazine	[no description available]	medium	1	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfadimethoxine	[no description available]	medium	1	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfamerazine	[no description available]	medium	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen
sulfamonomethoxine	[no description available]	medium	1	0	benzenes; sulfonamide
sulfanilamide	[no description available]	medium	1	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfaphenazole	[no description available]	medium	1	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulfapyridine	[no description available]	medium	1	0	pyridines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic
sulfisomidine	[no description available]	medium	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent
sulfisoxazole	[no description available]	medium	1	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
tolnaftate	[no description available]	medium	1	0	monothiocarbamic ester	antifungal drug
hydrocortisone acetate	[no description available]	medium	1	0	cortisol ester; tertiary alpha-hydroxy ketone
cortisone acetate	[no description available]	medium	1	0	corticosteroid hormone
corticosterone	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
prednisolone	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
spironolactone	[no description available]	medium	1	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
prednisolone acetate	[no description available]	medium	1	0	corticosteroid hormone
cyclobarbital	[no description available]	medium	1	0	barbiturates
allobarbital	[no description available]	medium	1	0	barbiturates
paramethasone	[no description available]	medium	1	0	fluorinated steroid
carbon tetrachloride	[no description available]	medium	1	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
phenylethyl alcohol	[no description available]	medium	1	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
4-nitrobenzoic acid	[no description available]	medium	1	0	nitrobenzoic acid
aniline	[no description available]	medium	1	0	anilines; primary arylamine
chloroform	[no description available]	medium	1	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
fluocinolone acetonide	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
4-hydroxypropiophenone	[no description available]	medium	1	0	acetophenones
n-pentanol	[no description available]	medium	1	0	pentanol; short-chain primary fatty alcohol	human metabolite; plant metabolite
acetonitrile	[no description available]	medium	1	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
tert-butyl alcohol	[no description available]	medium	1	0	tertiary alcohol	human xenobiotic metabolite
tert-amyl alcohol	[no description available]	medium	1	0	aliphatic alcohol; tertiary alcohol	protic solvent
triamcinolone acetonide	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
isobutyl alcohol	[no description available]	medium	1	0	alkyl alcohol; primary alcohol	Saccharomyces cerevisiae metabolite
2-butanol	[no description available]	medium	1	0	secondary alcohol
p-tert-amylphenol	[no description available]	medium	1	0	alkylbenzene
dehydrocholic acid	[no description available]	medium	1	0	12-oxo steroid; 3-oxo-5beta-steroid; 7-oxo steroid; oxo-5beta-cholanic acid	gastrointestinal drug
carbazole	[no description available]	medium	1	0	carbazole
quinoline	[no description available]	medium	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinolines
xanthenes	[no description available]	medium	1	0	xanthene
phenothiazine	[no description available]	medium	1	0	phenothiazine	ferroptosis inhibitor; plant metabolite; radical scavenger
thianthrene	[no description available]	medium	1	0	mancude organic heterotricyclic parent; organosulfur heterocyclic compound; thianthrenes
benzidine	[no description available]	medium	1	0	biphenyls; substituted aniline	carcinogenic agent
methyl benzoate	[no description available]	medium	1	0	benzoate ester; methyl ester	insect attractant; metabolite
ethyl benzoate	[no description available]	medium	1	0	benzoate ester; ethyl ester	flavouring agent; fragrance; volatile oil component
benzothiophene	[no description available]	medium	1	0	1-benzothiophenes; benzothiophene
benzothiazole	[no description available]	medium	1	0	benzothiazoles	environmental contaminant; plant metabolite; xenobiotic
cyclopentanol	[no description available]	medium	1	0	cyclopentanols
butylphen	[no description available]	medium	1	0	phenols	allergen
acetophenone	[no description available]	medium	1	0	acetophenones	animal metabolite; photosensitizing agent; xenobiotic
nitrobenzene	[no description available]	medium	1	0	nitroarene; nitrobenzenes
4-isopropylphenol	[no description available]	medium	1	0	phenols	flavouring agent
4-hydroxyacetophenone	[no description available]	medium	1	0	monohydroxyacetophenone	fungal metabolite; mouse metabolite; plant metabolite
4-chloronitrobenzene	[no description available]	medium	1	0	C-nitro compound
4-nitroaniline	[no description available]	medium	1	0	nitroaniline	bacterial xenobiotic metabolite
ethylbenzene	[no description available]	medium	1	0	alkylbenzene
benzyl chloride	[no description available]	medium	1	0	benzyl chlorides
benzonitrile	[no description available]	medium	1	0	benzenes; nitrile
methylaniline	[no description available]	medium	1	0	methylaniline; phenylalkylamine; secondary amine
anisole	[no description available]	medium	1	0	monomethoxybenzene	plant metabolite
phenetole	[no description available]	medium	1	0	aromatic ether
1,4-dibromobenzene	[no description available]	medium	1	0	dibromobenzene
4-bromophenol	[no description available]	medium	1	0	bromophenol	human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite
4-xylene	[no description available]	medium	1	0	xylene
isobutylmethylcarbinol	[no description available]	medium	1	0
3-chlorophenol	[no description available]	medium	2	0	monochlorophenol
bromobenzene	[no description available]	medium	1	0	bromoarene; bromobenzenes; volatile organic compound	hepatotoxic agent; mouse metabolite; non-polar solvent
cyclohexanol	[no description available]	medium	1	0	cyclohexanols; secondary alcohol	solvent
methyl cellosolve	[no description available]	medium	1	0	glycol ether	protic solvent; solvent
diethylamine	[no description available]	medium	1	0	secondary aliphatic amine
tetrahydrofuran	[no description available]	medium	1	0	cyclic ether; oxolanes; saturated organic heteromonocyclic parent; volatile organic compound	polar aprotic solvent
1,4-butanediol	[no description available]	medium	1	0	butanediol; glycol	neurotoxin; prodrug; protic solvent
1-hexanol	[no description available]	medium	1	0	hexanol; primary alcohol	alarm pheromone; antibacterial agent; fragrance; plant metabolite
1,5-pentanediol	[no description available]	medium	1	0	primary alcohol
heptanol	[no description available]	medium	1	0	heptanol; primary alcohol	flavouring agent; fragrance; gap junctional intercellular communication inhibitor; plant metabolite
mephobarbital	[no description available]	medium	1	0	barbiturates	anticonvulsant
ethyl-p-hydroxybenzoate	[no description available]	medium	32	0	ethyl ester; paraben	antifungal agent; antimicrobial food preservative; phytoestrogen; plant metabolite
2-methylbutanol	[no description available]	medium	1	0	alkyl alcohol; primary alcohol	Saccharomyces cerevisiae metabolite
p-cresyl acetate	[no description available]	medium	1	0	benzoate ester; phenols
3-hydroxyanisole	[no description available]	medium	1	0	monomethoxybenzene; phenols
mequinol	[no description available]	medium	1	0	methoxybenzenes; phenols	metabolite
phenanthridine	[no description available]	medium	1	0	azaarene; mancude organic heterotricyclic parent; phenanthridines; polycyclic heteroarene
acridines	[no description available]	medium	1	0	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
carbutamide	[no description available]	medium	1	0	benzenes; sulfonamide
4-fluorophenol	[no description available]	medium	1	0	fluorophenol; monofluorobenzenes
3-fluorophenol	[no description available]	medium	1	0
betamethasone	[no description available]	medium	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
fluorobenzenes	[no description available]	medium	1	0	monofluorobenzenes	NMR chemical shift reference compound
3,3-dimethyl-2-butanol	[no description available]	medium	1	0
chenodeoxycholic acid	[no description available]	medium	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
phloroglucinol dimethyl ether	[no description available]	medium	1	0	methoxybenzenes; phenols
1,3-propanediol	[no description available]	medium	1	0	propane-1,3-diols	metabolite; protic solvent
phenylacetylene	[no description available]	medium	1	0	benzenes
4-iodophenol	[no description available]	medium	1	0	iodophenol
3-bromophenol	[no description available]	medium	1	0
3,5-dichlorophenol	[no description available]	medium	1	0	dichlorophenol
iodobenzene	[no description available]	medium	1	0
3-isopropylphenol	[no description available]	medium	1	0
3-ethylphenol	[no description available]	medium	1	0	phenols
4-Ethoxyphenol	[no description available]	medium	1	0	aromatic ether; phenols
2-hexanol	[no description available]	medium	1	0	hexanol; secondary alcohol	human metabolite; plant metabolite; semiochemical
hexamethylene glycol	[no description available]	medium	1	0	diol; primary alcohol
4-propylphenol	[no description available]	medium	1	0	alkylbenzene
4-nitrophenyl acetate	[no description available]	medium	1	0	C-nitro compound; phenyl acetates
4-n-Butylphenol	[no description available]	medium	1	0	phenols
sulfamethomidine	[no description available]	medium	1	0	organic molecular entity
2-octanol	[no description available]	medium	1	0	octanol; secondary alcohol	plant metabolite; volatile oil component
hydrocortisone-17-butyrate	[no description available]	medium	1	0	butyrate ester; cortisol ester; primary alpha-hydroxy ketone	dermatologic drug; drug allergen
4-n-Pentylphenol	[no description available]	medium	1	0	phenols
4-ethylphenol	[no description available]	medium	2	0	phenols	fungal xenobiotic metabolite
isopentyl alcohol	[no description available]	medium	1	0	alkyl alcohol; primary alcohol; volatile organic compound	antifungal agent; Saccharomyces cerevisiae metabolite; xenobiotic metabolite
triamcinolone	[no description available]	medium	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
ursodeoxycholic acid	[no description available]	medium	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
progabide	[no description available]	medium	1	0	diarylmethane
1-n-butylimidazole	[no description available]	medium	1	0
phenoxazine	[no description available]	medium	1	0	phenoxazine	ferroptosis inhibitor; radical scavenger
cresatin	[no description available]	medium	1	0	benzoate ester; phenols
3-propylphenol	[no description available]	medium	1	0
cyclobutanol	[no description available]	medium	1	0
1-benzylimidazole	[no description available]	medium	1	0
triflumizol	[no description available]	medium	1	0
1-adamantaneacetic acid	[no description available]	medium	1	0
cholic acid	[no description available]	medium	2	0	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
cortisone	[no description available]	medium	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
griseofulvin	[no description available]	medium	1	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
3-coumaric acid	[no description available]	medium	1	0	3-coumaric acid
trans-4-coumaric acid	[no description available]	medium	1	0	4-coumaric acid	food component; mouse metabolite; plant metabolite
cinnarizine	[no description available]	medium	1	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
thiopental	[no description available]	medium	1	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
dinoprostone	[no description available]	medium	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
epoprostenol	[no description available]	medium	1	0	prostaglandins I	mouse metabolite
butylbenzyl phthalate	[no description available]	medium	1	0	benzyl ester
tetrachlorodian	[no description available]	medium	1	0	bisphenol
2,2',4,4'-tetrahydroxybenzophenone	[no description available]	medium	2	0
4-tert-octylphenol	[no description available]	medium	1	0	alkylbenzene
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	[no description available]	medium	1	0	bisphenol
4-oxy-6-(4-oxybezoyloxy)dauc-8,9-en	[no description available]	medium	1	0
zeranol	[no description available]	medium	1	0	macrolide
miltefosine	[no description available]	medium	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
benzonidazole	[no description available]	medium	1	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
gibbilimbol b	[no description available]	medium	1	0
gibbilimbol a	[no description available]	medium	1	0
vanillin	[no description available]	medium	1	0	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite
vanillic acid	[no description available]	medium	1	0	methoxybenzoic acid; monohydroxybenzoic acid	plant metabolite
methyl vanillate	[no description available]	medium	1	0	aromatic ether; benzoate ester; phenols	antioxidant; plant metabolite
ferulic acid	[no description available]	medium	1	0	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
penicillin g	[no description available]	medium	1	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
n-butyl gallate	[no description available]	medium	1	0
octyl gallate	[no description available]	medium	1	0	gallate ester	food antioxidant; hypoglycemic agent; plant metabolite
4-phenoxyphenol	[no description available]	medium	1	0	phenoxyphenol
bis(4-oxyphenyl)sulfide	[no description available]	medium	2	0	phenols
2-ethoxybenzoic acid	[no description available]	medium	1	0
2-chloro-1,4-dimethoxybenzene	[no description available]	medium	1	0	dimethoxybenzene
gw 3965	[no description available]	medium	1	0	diarylmethane
t0901317	[no description available]	medium	1	0
way 252623	[no description available]	medium	1	0
incb-018424	[no description available]	medium	1	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
sr9238	[no description available]	medium	1	0
vitexin	[no description available]	medium	1	0	C-glycosyl compound; trihydroxyflavone	antineoplastic agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite; platelet aggregation inhibitor
hyperoside	[no description available]	medium	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
myricetin	[no description available]	medium	1	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
propylparaben	[no description available]	medium	163	1	benzoate ester; paraben; phenols	antifungal agent; antimicrobial agent
benzylparaben	[no description available]	medium	11	0	benzoate ester; benzyl ester
methylparaben	[no description available]	medium	66	0	paraben	antifungal agent; antimicrobial food preservative; neuroprotective agent; plant metabolite
bisphenol a	[no description available]	medium	6	0	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen
diethylhexyl phthalate	[no description available]	medium	5	0	diester; phthalate ester	androstane receptor agonist; apoptosis inhibitor; plasticiser
triclosan	[no description available]	medium	6	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
2,5-dichlorophenol	[no description available]	medium	2	0	dichlorophenol	human xenobiotic metabolite
isobutylparaben	[no description available]	medium	5	0	4-hydroxybenzoate ester
sulforaphane	[no description available]	medium	1	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
peroxymonosulfate	[no description available]	medium	1	0	sulfur oxide; sulfur oxoanion
ferrihydrite	[no description available]	medium	1	0
diethyl phthalate	[no description available]	medium	3	1	diester; ethyl ester; phthalate ester	neurotoxin; plasticiser; teratogenic agent
silver	[no description available]	medium	2	0	copper group element atom; elemental silver	Escherichia coli metabolite
aluminum chloride	[no description available]	medium	2	0	aluminium coordination entity	Lewis acid
thyroxine	[no description available]	medium	2	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
triiodothyronine	[no description available]	medium	1	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
caffeine	[no description available]	medium	8	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
4-cumylphenol	[no description available]	medium	1	0	diarylmethane
dibutyl phthalate	[no description available]	medium	3	1	diester; phthalate ester	EC 3.2.1.20 (alpha-glucosidase) inhibitor; environmental contaminant; metabolite; plasticiser; teratogenic agent
chlorine	[no description available]	medium	1	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
phenyl acetate	[no description available]	medium	1	0	benzenes; phenyl acetates
sorbic acid	[no description available]	medium	2	0	alpha,beta-unsaturated monocarboxylic acid; sorbic acid
sodium acetate	[no description available]	medium	1	0
chlorophyll a	[no description available]	medium	1	0	chlorophyll; methyl ester	cofactor
benzo(a)pyrene	[no description available]	medium	2	0	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite
perfluorooctane sulfonic acid	[no description available]	medium	2	0	perfluoroalkanesulfonic acid	antilipemic drug; persistent organic pollutant
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	[no description available]	medium	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
propyl gallate	[no description available]	medium	3	0	trihydroxybenzoic acid
cysteine	[no description available]	medium	1	0	cysteinium	fundamental metabolite
sulisobenzone	[no description available]	medium	1	0	benzophenones
benzophenone	[no description available]	medium	2	0	benzophenones	photosensitizing agent; plant metabolite
malondialdehyde	[no description available]	medium	1	0	dialdehyde	biomarker
phthalic acid	[no description available]	medium	1	0	benzenedicarboxylic acid	human xenobiotic metabolite
fluorescein-5-isothiocyanate	[no description available]	medium	1	0	fluorescein isothiocyanate
precirol	[no description available]	medium	1	0
titanium	[no description available]	medium	2	0	titanium group element atom
titanium dioxide	[no description available]	medium	2	0	titanium oxides	food colouring
valproic acid	[no description available]	medium	2	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
cerium	[no description available]	medium	1	0	f-block element atom; lanthanoid atom
ceric oxide	[no description available]	medium	1	0	cerium molecular entity; metal oxide
ruthenium	[no description available]	medium	1	0	iron group element atom; platinum group metal atom
permanganate	[no description available]	medium	1	0	manganese oxoacid
camphor, (+-)-isomer	[no description available]	medium	1	0	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite
enzacamene	[no description available]	medium	1	0
acetaminophen	[no description available]	medium	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
octylmethoxycinnamate	[no description available]	medium	2	0	cinnamate ester
2,3,4,6-tetrachlorophenol	[no description available]	medium	1	0	tetrachlorophenol	xenobiotic metabolite
oxybenzone	[no description available]	medium	2	0	hydroxybenzophenone; monomethoxybenzene	dermatologic drug; environmental contaminant; protective agent; ultraviolet filter; xenobiotic
deoxyguanosine	[no description available]	medium	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2,4-dichlorophenol	[no description available]	medium	1	0	dichlorophenol
8-hydroxy-2'-deoxyguanosine	[no description available]	medium	1	0	guanosines	biomarker
pyrethrins	[no description available]	medium	1	0
tetramethrin	[no description available]	medium	1	0	cyclopropanecarboxylate ester; maleimides; phthalimide insecticide	pyrethroid ester insecticide
3-nitrotyrosine	[no description available]	medium	1	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
adenosine monophosphate	[no description available]	medium	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
tyrosine	[no description available]	medium	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
glutathione disulfide	[no description available]	medium	2	0	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
ethyl cellulose	[no description available]	medium	1	0	glycoside
cellulose	[no description available]	medium	3	0	glycoside
alfuzosin	[no description available]	medium	1	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
quinazolines	[no description available]	medium	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
methane	[no description available]	medium	1	0	alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound	bacterial metabolite; fossil fuel; greenhouse gas
deuterium	[no description available]	medium	1	0	dihydrogen
4-hydroxyhippuric acid	[no description available]	medium	1	0	N-acylglycine	human blood serum metabolite
dihydrotestosterone	[no description available]	medium	1	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
taxifolin	[no description available]	medium	1	0	taxifolin	metabolite
quercetin	[no description available]	medium	2	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
chlorine	[no description available]	medium	1	0	diatomic chlorine; gas molecular entity	bleaching agent
ozone	[no description available]	medium	1	0	elemental molecule; gas molecular entity; reactive oxygen species; triatomic oxygen	antiseptic drug; disinfectant; electrophilic reagent; greenhouse gas; mutagen; oxidising agent; tracer
4-vinyl-1-cyclohexene dioxide	[no description available]	medium	1	0	epoxide	carcinogenic agent
singlet oxygen	[no description available]	medium	1	0	chalcogen; monoatomic oxygen; nonmetal atom	macronutrient
ethinyl estradiol	[no description available]	medium	1	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
sodium lactate	[no description available]	medium	1	0	lactate salt; organic sodium salt	food acidity regulator; food preservative
3,4-dihydroxybenzylamine	[no description available]	medium	1	0	catechols
methylcellulose	[no description available]	medium	1	0
pyrazolanthrone	[no description available]	medium	1	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
chlorpyrifos	[no description available]	medium	1	0	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
trifluralin	[no description available]	medium	1	0	(trifluoromethyl)benzenes; C-nitro compound; substituted aniline	agrochemical; environmental contaminant; herbicide; xenobiotic
4-nonylphenol	[no description available]	medium	1	0	phenols	environmental contaminant
cisapride	[no description available]	medium	1	0	benzamides
naphthoresorcinol	[no description available]	medium	1	0
phloretin	[no description available]	medium	1	0	dihydrochalcones	antineoplastic agent; plant metabolite
chloramphenicol	[no description available]	medium	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
2-naphthol	[no description available]	medium	2	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
dinitrochlorobenzene	[no description available]	medium	1	0	C-nitro compound; monochlorobenzenes	allergen; epitope; sensitiser
2,4-dichloro-1-nitrobenzene	[no description available]	medium	1	0
sodium dodecyl sulfate	[no description available]	medium	1	0	organic sodium salt	detergent; protein denaturant
salicylates	[no description available]	medium	1	0	monohydroxybenzoate	plant metabolite
angiotensin ii	[no description available]	medium	1	0	amino acid zwitterion; angiotensin II	human metabolite
acyclovir	[no description available]	medium	2	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
betadex	[no description available]	medium	1	0	cyclodextrin
barium	[no description available]	medium	1	0	alkaline earth metal atom; elemental barium
enkephalin, leucine	[no description available]	medium	1	0	pentapeptide; peptide zwitterion	analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite
1-naphthol	[no description available]	medium	1	0	naphthol	genotoxin; human xenobiotic metabolite
kyotorphin	[no description available]	medium	1	0	dipeptide
cholecystokinin	[no description available]	medium	1	0
mercaptopurine	[no description available]	medium	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
mannitol	[no description available]	medium	2	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
limonene	[no description available]	medium	1	0	cycloalkene; p-menthadiene	human metabolite
oleic acid	[no description available]	medium	1	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
1-geranylazacycloheptan-2-one	[no description available]	medium	1	0
polidocanol	[no description available]	medium	1	0	hydroxypolyether	hepatotoxic agent; nonionic surfactant; sclerotherapy agent
tamoxifen	[no description available]	medium	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
hydrogen	[no description available]	medium	1	0	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
urea	[no description available]	medium	1	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
arginine	[no description available]	medium	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
tosyllysine chloromethyl ketone	[no description available]	medium	1	0	sulfonic acid derivative
allopurinol	[no description available]	medium	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
vitamin k semiquinone radical	[no description available]	medium	1	0
Acetylpheneturide	[no description available]	low	0	0	organic molecular entity
afloqualone	[no description available]	low	0	0	organic molecular entity
aranidipine	[no description available]	low	0	0	organic molecular entity
bromazepam	[no description available]	low	0	0	organic molecular entity
seratrodast	[no description available]	low	0	0	organic molecular entity
brotizolam	[no description available]	low	0	0	organic molecular entity
cadralazine	[no description available]	low	0	0	organic molecular entity
carbazilquinone	[no description available]	low	0	0	organic molecular entity
clinofibrate	[no description available]	low	0	0	organic molecular entity
clotiazepam	[no description available]	low	0	0	organic molecular entity
cyclofenil	[no description available]	low	0	0	organic molecular entity
ebastine	[no description available]	low	0	0	organic molecular entity
emorfazone	[no description available]	low	0	0	organic molecular entity
ethenzamide	[no description available]	low	0	0	organic molecular entity
ethyl loflazepate	[no description available]	low	0	0	organic molecular entity
etizolam	[no description available]	low	0	0	organic molecular entity
amidoline	[no description available]	low	0	0	organic molecular entity
floctafenine	[no description available]	low	0	0	organic molecular entity
flopropione	[no description available]	low	0	0	organic molecular entity
fp 83	[no description available]	low	0	0	organic molecular entity
flutazolam	[no description available]	low	0	0	hemiaminal ether; organic molecular entity
flutoprazepam	[no description available]	low	0	0	organic molecular entity
glybuzole	[no description available]	low	0	0	organic molecular entity
haloxazolam	[no description available]	low	0	0	organic molecular entity
ibuprofen piconol	[no description available]	low	0	0	organic molecular entity
iothalamic acid	[no description available]	low	0	0	organic molecular entity
iotrolan	[no description available]	low	0	0	organic molecular entity
iotroxic acid	[no description available]	low	0	0	organic molecular entity
mazindol	[no description available]	low	0	0	organic molecular entity
mefruside	[no description available]	low	0	0	organic molecular entity
meprobamate	[no description available]	low	0	0	organic molecular entity
metharbital	[no description available]	low	0	0	organic molecular entity
methyprylon	[no description available]	low	0	0	organic molecular entity
myristicin	[no description available]	low	0	0	organic molecular entity	metabolite
niceritrol	[no description available]	low	0	0	organic molecular entity
osalmide	[no description available]	low	0	0	organic molecular entity
oxazolam	[no description available]	low	0	0	hemiaminal ether; organic molecular entity
oxypertine	[no description available]	low	0	0	organic molecular entity
pirenoxine	[no description available]	low	0	0	organic molecular entity
propyliodone	[no description available]	low	0	0	organic molecular entity
repirinast	[no description available]	low	0	0	organic molecular entity
simfibrate	[no description available]	low	0	0	organic molecular entity
sobuzoxane	[no description available]	low	0	0	organic molecular entity
sulthiame	[no description available]	low	0	0	organic molecular entity
tazanolast	[no description available]	low	0	0	organic molecular entity
tofisopam	[no description available]	low	0	0	organic molecular entity
3-(2',4',5'-triethoxybenzoyl)propionic acid	[no description available]	low	0	0	organic molecular entity
vesnarinone	[no description available]	low	0	0	organic molecular entity
cn 100	[no description available]	low	0	0	organic molecular entity
procaine hydrochloride	[no description available]	low	0	0	organic molecular entity
lysine	[no description available]	low	0	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
Mebutamate	[no description available]	low	0	0	organic molecular entity
methandrostenolone	[no description available]	low	0	0	organic molecular entity
tetramethylammonium chloride	[no description available]	low	0	0	organic molecular entity
methsuximide	[no description available]	low	0	0	organic molecular entity
1-phenylpropanol	[no description available]	low	0	0	organic molecular entity
efloxate	[no description available]	low	0	0	organic molecular entity
sulfan blue	[no description available]	low	0	0	organic molecular entity
1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt	[no description available]	low	0	0	organic molecular entity
cycloguanil hydrochloride	[no description available]	low	0	0	hydrochloride; organic molecular entity
nicarbazin	[no description available]	low	0	0	organic molecular entity
fluocinonide	[no description available]	low	0	0	organic molecular entity
copper gluconate	[no description available]	low	0	0	organic molecular entity
naphazoline hydrochloride	[no description available]	low	0	0	organic molecular entity
doxylamine succinate	[no description available]	low	0	0	organic molecular entity
carbamylhydrazine monohydrochloride	[no description available]	low	0	0	organic molecular entity
Berberine chloride (TN)	[no description available]	low	0	0	organic molecular entity
isosorbide	[no description available]	low	0	0	organic molecular entity
bucetin	[no description available]	low	0	0	organic molecular entity
tetradecyltrimethylammonium bromide	[no description available]	low	0	0	organic molecular entity
rimantadine hydrochloride	[no description available]	low	0	0	organic molecular entity
nitrofen	[no description available]	low	0	0	organic molecular entity	EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
perlapine	[no description available]	low	0	0	organic molecular entity
clorexolone	[no description available]	low	0	0	organic molecular entity
stavudine	[no description available]	low	0	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
iobenzamic acid	[no description available]	low	0	0	organic molecular entity
Brilliant Blue	[no description available]	low	0	0	organic molecular entity
pyrodifenium bromide	[no description available]	low	0	0	organic molecular entity
didecyldimethylammonium chloride	[no description available]	low	0	0	organic molecular entity
iocarmic acid	[no description available]	low	0	0	organic molecular entity
bisoxatin acetate	[no description available]	low	0	0	organic molecular entity
levamisole hydrochloride	[no description available]	low	0	0	organic molecular entity
halazepam	[no description available]	low	0	0	organic molecular entity
nicomol	[no description available]	low	0	0	organic molecular entity
feprazone	[no description available]	low	0	0	organic molecular entity
b 10610	[no description available]	low	0	0	organic molecular entity
haloperidol decanoate	[no description available]	low	0	0	organic molecular entity
pinacidil	[no description available]	low	0	0	organic molecular entity
loxiglumide	[no description available]	low	0	0	organic molecular entity
saquinavir monomethanesulfonate	[no description available]	low	0	0	organic molecular entity
Pronetalol hydrochloride	[no description available]	low	0	0	organic molecular entity
phenelzine sulfate	[no description available]	low	0	0	organic molecular entity
magnesium peroxide	[no description available]	low	0	0	organic molecular entity
dexamethasone 21-palmitate	[no description available]	low	0	0	organic molecular entity
rotenolone	[no description available]	low	0	0	organic molecular entity	metabolite
nilverm	[no description available]	low	0	0	organic molecular entity
diumide	[no description available]	low	0	0	organic molecular entity
docarpamine	[no description available]	low	0	0	organic molecular entity
clobetasone butyrate	[no description available]	low	0	0	organic molecular entity
enocitabine	[no description available]	low	0	0	organic molecular entity
ranimustine	[no description available]	low	0	0	organic molecular entity
protizinic acid	[no description available]	low	0	0	organic molecular entity
nipradilol	[no description available]	low	0	0	organic molecular entity
panipenem	[no description available]	low	0	0	organic molecular entity
p-Aminobenzamidine dihydrochloride	[no description available]	low	0	0	organic molecular entity
aucubin	[no description available]	low	0	0	organic molecular entity	metabolite
catalpol	[no description available]	low	0	0	organic molecular entity	metabolite
halopredone acetate	[no description available]	low	0	0	organic molecular entity
3-acetyllupeol	[no description available]	low	0	0	organic molecular entity	metabolite
phenmetrazine hydrochloride	[no description available]	low	0	0	organic molecular entity
isometamidium chloride	[no description available]	low	0	0	organic molecular entity
melanotan-ii	[no description available]	low	0	0	organic molecular entity
anecortave acetate	[no description available]	low	0	0	organic molecular entity
aluminum phthalocyanine	[no description available]	low	0	0	organic molecular entity
olprinone	[no description available]	low	0	0	organic molecular entity
clidanac	[no description available]	low	0	0	organic molecular entity
enkephalin-met, arg(6)-phe(7)-	[no description available]	low	0	0	organic molecular entity
angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-	[no description available]	low	0	0	organic molecular entity
ramatroban	[no description available]	low	0	0	organic molecular entity
3-acetylpyridine adenine dinucleotide	[no description available]	low	0	0	organic molecular entity
iguratimod	[no description available]	low	0	0	organic molecular entity
blonanserin	[no description available]	low	0	0	organic molecular entity
fudosteine	[no description available]	low	0	0	organic molecular entity
perlolyrine	[no description available]	low	0	0	organic molecular entity	metabolite
timepidium bromide	[no description available]	low	0	0	organic molecular entity
2-(2-hydroxy-4-methylphenyl)aminothiazole	[no description available]	low	0	0	organic molecular entity
cupric hydroxide	[no description available]	low	0	0	organic molecular entity
beta-mercaptolactate cysteine disulfide	[no description available]	low	0	0	organic molecular entity
s 8308	[no description available]	low	0	0	organic molecular entity
farrerol	[no description available]	low	0	0	organic molecular entity	metabolite
hydroxylamine hydrochloride	[no description available]	low	0	0	organic molecular entity
cyclo(l-phe-l-pro)	[no description available]	low	0	0	organic molecular entity	metabolite
gestonorone caproate	[no description available]	low	0	0	organic molecular entity
epitiostanol	[no description available]	low	0	0	organic molecular entity
halcinonide	[no description available]	low	0	0	organic molecular entity	SMO receptor agonist
oxendolone	[no description available]	low	0	0	organic molecular entity
dironyl	[no description available]	low	0	0	organic molecular entity
ao 128	[no description available]	low	0	0	organic molecular entity
ditiocarb sodium	[no description available]	low	0	0	organic molecular entity
aceglatone	[no description available]	low	0	0	organic molecular entity
opc-2009	[no description available]	low	0	0	organic molecular entity
bucillamine	[no description available]	low	0	0	organic molecular entity
cefsulodin sodium	[no description available]	low	0	0	organic molecular entity
n-(3,4-dimethoxyphenyl)-n-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-4-nitrobenzamide hydrochloride	[no description available]	low	0	0	organic molecular entity
4E2RCat	[no description available]	low	0	0	organic molecular entity
potassium oxonate	[no description available]	low	0	0	organic molecular entity
p-aminosalicylic acid monosodium salt	[no description available]	low	0	0	organic molecular entity
1-deoxyfructose	[no description available]	low	0	0	organic molecular entity
ungeremine	[no description available]	low	0	0	organic molecular entity	metabolite
ethyl 4-(3-oxo-2,3-dihydroisothiazol-2-yl)benzoate	[no description available]	low	0	0	organic molecular entity
pyrantel pamoate	[no description available]	low	0	0	organic molecular entity
chlorpheniramine maleate	[no description available]	low	0	0	organic molecular entity
dexchlorpheniramine maleate	[no description available]	low	0	0	organic molecular entity
gsh-prostaglandin a1	[no description available]	low	0	0	organic molecular entity
lafutidine	[no description available]	low	0	0	organic molecular entity
pheniramine maleate	[no description available]	low	0	0	organic molecular entity
sf 837	[no description available]	low	0	0	organic molecular entity
gefarnate	[no description available]	low	0	0	organic molecular entity
sorivudine	[no description available]	low	0	0	organic molecular entity
ornoprostil	[no description available]	low	0	0	organic molecular entity
cd 3400	[no description available]	low	0	0	organic molecular entity
rokitamycin	[no description available]	low	0	0	organic molecular entity
prednisolone farnesylate	[no description available]	low	0	0	organic molecular entity
dinoprost tromethamine	[no description available]	low	0	0	organic molecular entity
phenoxybenzamine hydrochloride	[no description available]	low	0	0	organic molecular entity
proscillaridin	[no description available]	low	0	0	organic molecular entity
goserelin	[no description available]	low	0	0	organic molecular entity
azodicarbonamide	[no description available]	low	0	0	organic molecular entity
tulobuterol hydrochloride	[no description available]	low	0	0	organic molecular entity
maxacalcitol	[no description available]	low	0	0	organic molecular entity
longiborneol	[no description available]	low	0	0	organic molecular entity
falcarindiol	[no description available]	low	0	0	organic molecular entity	metabolite
ozagrel, monohydrochloride, (e)-isomer	[no description available]	low	0	0	organic molecular entity
microcystin rr	[no description available]	low	0	0	microcystin; organic molecular entity	bacterial metabolite; environmental contaminant; xenobiotic
lankacidins	[no description available]	low	0	0	organic molecular entity
romurtide	[no description available]	low	0	0	organic molecular entity
ciclesonide	[no description available]	low	0	0	organic molecular entity
fursultiamin monohydrochloride	[no description available]	low	0	0	organic molecular entity
pentagastrin	[no description available]	low	0	0	organic molecular entity
mepitiostane	[no description available]	low	0	0	organic molecular entity
calcium sulfide	[no description available]	low	0	0	organic molecular entity
barettin	[no description available]	low	0	0	organic molecular entity
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide, (r)-isomer,	[no description available]	low	0	0	organic molecular entity
nociceptin	[no description available]	low	0	0	organic molecular entity; polypeptide	human metabolite; rat metabolite
sodium salicylate	[no description available]	low	0	0	organic molecular entity
n-(2-methylbenzyl)linoleamide	[no description available]	low	0	0	organic molecular entity
halisulfate 1	[no description available]	low	0	0	organic molecular entity	metabolite
novobiocin sodium	[no description available]	low	0	0	organic molecular entity
cefoperazone sodium	[no description available]	low	0	0	organic molecular entity
osteum	[no description available]	low	0	0	organic molecular entity
cefoxitin sodium	[no description available]	low	0	0	organic molecular entity
dexon (fungicide), sodium salt	[no description available]	low	0	0	organic molecular entity
zinacef	[no description available]	low	0	0	organic molecular entity
sodium iodate	[no description available]	low	0	0	organic molecular entity
pyrithiobac sodium	[no description available]	low	0	0	organic molecular entity
cortisol succinate, sodium salt	[no description available]	low	0	0	organic molecular entity
sodium 2,6-dichloroindophenol	[no description available]	low	0	0	organic molecular entity
quinupristin-dalfopristin	[no description available]	low	0	0	organic molecular entity
gyy 4137	[no description available]	low	0	0	organic molecular entity
monanchocidin	[no description available]	low	0	0	organic molecular entity	metabolite
spinetoram	[no description available]	low	0	0	organic molecular entity
gimeracil	[no description available]	low	0	0	organic molecular entity
suvanine	[no description available]	low	0	0	organic molecular entity	metabolite
vt-1161	[no description available]	low	0	0	organic molecular entity
3-hydroxykynurenine glucoside	[no description available]	low	0	0	organic molecular entity
dBET6	[no description available]	low	0	0	organic molecular entity
MZ1	[no description available]	low	0	0	organic molecular entity
staphylopine(1-)	[no description available]	low	0	0	organic molecular entity
pseudopaline(2-)	[no description available]	low	0	0	organic molecular entity
valtrex	[no description available]	low	0	0	organic molecular entity
hlo 7	[no description available]	low	0	0	organic molecular entity
7-deazaguanine	[no description available]	low	0	0	organic molecular entity
7,8-dihydropterin	[no description available]	low	0	0	organic molecular entity; pterins
pteroylpentaglutamic acid	[no description available]	low	0	0	organic molecular entity
amicoumacin a	[no description available]	low	0	0	organic molecular entity

Article	Year
Cardio- and neuro-toxic effects of four parabens on Daphnia magna. Ecotoxicology and environmental safety, Volume: 268	2023
Disparate toxicity mechanisms of parabens with different alkyl chain length in freshwater biofilms: Ecological hazards associated with antibiotic resistome. The Science of the total environment, Jul-10, Volume: 881	2023
Thirteen-week subcutaneous repeated dose toxicity study of butylparaben and its toxicokinetics in rats. Archives of toxicology, Volume: 95, Issue: 6	2021
Abnormal steroidogenesis, oxidative stress, and reprotoxicity following prepubertal exposure to butylparaben in mice and protective effect of Curcuma longa. Environmental science and pollution research international, Volume: 28, Issue: 5	2021
Assessment of hepatotoxicity and dermal toxicity of butyl paraben and methyl paraben using HepG2 and HDFn in vitro models. Toxicology in vitro : an international journal published in association with BIBRA, Volume: 55	2019
Comparative toxic effects of butylparaben sodium, sodium diacetate and potassium sorbate to Dunaliella tertiolecta and HL7702 cells. Food & function, Dec-13, Volume: 8, Issue: 12	2017
Genotoxic effects in transformed and non-transformed human breast cell lines after exposure to silver nanoparticles in combination with aluminium chloride, butylparaben or di-n-butylphthalate. Toxicology in vitro : an international journal published in association with BIBRA, Volume: 45, Issue: Pt 1	2017
Protective role of metabolism by intestinal microflora in butyl paraben-induced toxicity in HepG2 cell cultures. Toxicology letters, Sep-03, Volume: 213, Issue: 2	2012
Preliminary ecological risk assessment of butylparaben and benzylparaben -1. Removal efficiency in wastewater treatment, acute/chronic toxicity for aquatic organisms, and effects on medaka gene expression. Environmental sciences : an international journal of environmental physiology and toxicology, Volume: 14 Suppl	2007
Developmental toxicity evaluation of butylparaben in Sprague-Dawley rats. Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 71, Issue: 4	2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Exposure to parabens and dysglycemia: Insights from a Chinese population. Chemosphere, Volume: 340	2023
Effects of butylparaben exposure on thyroid peroxidase (TPO) and type 1 iodothyronine deiodinase (D1) in female Wistar rats. Toxicology, Volume: 443	2020
Estrogenic and anti-estrogenic activity of butylparaben, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate and their binary mixtures on two estrogen responsive cell lines (T47D-Kbluc, MCF-7). Journal of applied toxicology : JAT, Volume: 38, Issue: 7	2018
Metabolism and elimination of methyl, iso- and n-butyl paraben in human urine after single oral dosage. Archives of toxicology, Volume: 90, Issue: 11	2016
A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben. Toxicology, Jun-05, Volume: 332	2015
Late-life effects on rat reproductive system after developmental exposure to mixtures of endocrine disrupters. Reproduction (Cambridge, England), Volume: 147, Issue: 4	2014
Ruthenium nanoparticles supported on CeO2 for catalytic permanganate oxidation of butylparaben. Environmental science & technology, Nov-19, Volume: 47, Issue: 22	2013
Metabolism and disposition of [14C]n-butyl-p-hydroxybenzoate in male and female Harlan Sprague Dawley rats following oral administration and dermal application. Xenobiotica; the fate of foreign compounds in biological systems, Volume: 43, Issue: 2	2013
Parabens enable suspension growth of MCF-10A immortalized, non-transformed human breast epithelial cells. Journal of applied toxicology : JAT, Volume: 33, Issue: 5	2013
Do parabens have the ability to interfere with steroidogenesis? Toxicological sciences : an official journal of the Society of Toxicology, Volume: 106, Issue: 1	2008
Lack of effect of butylparaben and methylparaben on the reproductive system in male rats. Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 83, Issue: 2	2008
[Enhancement of di-n-butyl phthalate on the estrogenic activities of esters of p-hydroxybenzoic acid]. Wei sheng yan jiu = Journal of hygiene research, Volume: 36, Issue: 3	2007
Developmental toxicity evaluation of butylparaben in Sprague-Dawley rats. Birth defects research. Part B, Developmental and reproductive toxicology, Volume: 71, Issue: 4	2004
Determination of cisapride, its oxidation product, propyl and butyl parabens in pharmaceutical dosage form by reversed-phase liquid chromatography. Journal of pharmaceutical and biomedical analysis, Dec-04, Volume: 33, Issue: 5	2003
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

butylparaben

Cross-References

Synonyms (166)

Research Excerpts

Overview

Effects

Actions

Drug Classes (1)

Protein Targets (53)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (264)

Molecular Functions (84)

Ceullar Components (44)

Bioassays (68)

Research

Studies (187)

Study Types

Research Highlights

Safety/Toxicity (10)

Pharmacokinetics (1)

Bioavailability (3)

Dosage (14)

Interactions (2)

Condition	Relationship Strength	Studies
Abnormalities, Drug-Induced	low	2
Abnormality, Heart	low	1
Abortion, Spontaneous	low	1
Abortion, Tubal	low	1
Acute Liver Injury, Drug-Induced	low	1
Adolescent Obesity	low	1
Adolescent Overweight	low	1
Aging	low	1
Amyloidosis	low	1
Anasarca	low	1
Anemia, Fanconi	low	1
Anxiety	low	1
Autism	low	2
Autism, Early Infantile	low	2
Autism, Infantile	low	2
Autistic Disorder	low	2
Basophilic Leukemia, Acute	low	1
Birth Weight	low	2
Body Weight	low	5
Brain Diseases	low	1
Brain Disorders	low	1
Breast Cancer	low	4
Breast Carcinoma	low	4
Breast Neoplasms	low	4
Breast Tumors	low	4
Cadaver	low	1
Cancer of Breast	low	4
Cancer of Cervix	low	1
Cancer of Endometrium	low	1
Cancer of the Breast	low	4
Cancer of the Cervix	low	1
Cancer of the Endometrium	low	1
Cancer of the Uterine Cervix	low	1
Carcinoma of Endometrium	low	1
Cardiomyopathies	low	1
Cardiomyopathies, Primary	low	1
Cardiomyopathies, Secondary	low	1
Central Nervous System Disorders, Intracranial	low	1
Central Nervous System Intracranial Disorders	low	1
Cervical Cancer	low	1
Cervical Neoplasms	low	1
Cervix Cancer	low	1
Cervix Dysplasia	low	1
Cervix Neoplasms	low	1
Chemical and Drug Induced Liver Injury	low	1
Chemically-Induced Liver Toxicity	low	1
Child Obesity	low	1
Childhood Obesity	low	1
Childhood Onset Obesity	low	1
Childhood Overweight	low	1
CNS Disorders, Intracranial	low	1
Congenital Heart Defect	low	1
Congenital Heart Defects	low	1
Congenital Heart Disease	low	1
Congenital Zika Syndrome	low	1
Congenital Zika Virus Infection	low	1
Contact Dermatitis	low	2
Corpse	low	1
Defects, Congenital Heart	low	1
Degenerative Diseases, Central Nervous System	low	1
Degenerative Diseases, Nervous System	low	1
Degenerative Diseases, Neurologic	low	1
Degenerative Diseases, Spinal Cord	low	1
Degenerative Neurologic Diseases	low	1
Degenerative Neurologic Disorders	low	1
Delayed Effects, Prenatal Exposure	low	9
Dermatitis Venenata	low	2
Dermatitis, Contact	low	2
Diabetes Mellitus, Adult-Onset	low	1
Diabetes Mellitus, Ketosis-Resistant	low	1
Diabetes Mellitus, Maturity-Onset	low	1
Diabetes Mellitus, Non Insulin Dependent	low	1
Diabetes Mellitus, Non-Insulin-Dependent	low	1
Diabetes Mellitus, Noninsulin Dependent	low	1
Diabetes Mellitus, Noninsulin-Dependent	low	1
Diabetes Mellitus, Slow-Onset	low	1
Diabetes Mellitus, Stable	low	1
Diabetes Mellitus, Type 2	low	1
Diabetes Mellitus, Type II	low	1
Disease Models, Animal	low	2
Diseases of Endocrine System	low	1
Dropsy	low	1
Drug-Induced Abnormalities	low	2
Drug-Induced Acute Liver Injury	low	1
Drug-Induced Liver Disease	low	1
Drug-Induced Liver Injury	low	1
Early Pregnancy Loss	low	1
Eczema, Contact	low	2
Edema	low	1
Encephalitis, Polio	low	1
Encephalon Diseases	low	1
Encephalopathy	low	1
Endocrine Diseases	low	1
Endocrine System Diseases	low	1
Endometrial Cancer	low	1
Endometrial Carcinoma	low	1
Endometrial Neoplasms	low	1
Endometrium Cancer	low	1
Epidemic Acute Poliomyelitis	low	1
Erythema	low	1
Experimental Leukemia	low	1
Experimental Leukemias	low	1
Experimental Neoplasms	low	1
Fanconi Anemia	low	1
Fanconi Hypoplastic Anemia	low	1
Fanconi Pancytopenia	low	1
Fanconi Panmyelopathy	low	1
Fanconi's Anemia	low	1
Fever, Zika	low	1
Heart Abnormalities	low	1
Heart Defect, Congenital	low	1
Heart Defects, Congenital	low	1
Heart Failure, Systolic	low	1
Heart, Malformation Of	low	1
Hepatitis, Drug-Induced	low	1
Hepatitis, Toxic	low	1
Human Mammary Carcinoma	low	4
Hydrops	low	1
Hypermelanosis	low	1
Hyperpigmentation	low	1
Hypersensitivity, Contact	low	2
Infant Obesity	low	1
Infant Overweight	low	1
Infantile Obesity	low	1
Infantile Paralysis	low	1
Inflammation	low	3
Innate Inflammatory Response	low	3
Intracranial Central Nervous System Disorders	low	1
Intracranial CNS Disorders	low	1
Invasiveness, Neoplasm	low	1
Kanner's Syndrome	low	2
Late Effects, Prenatal Exposure	low	9
Leukemia Model, Animal	low	1
Leukemia, Basophilic, Acute	low	1
Leukemia, Experimental	low	1
Leukemias, Experimental	low	1
Liver Injury, Drug-Induced	low	1
Liver Injury, Drug-Induced, Acute	low	1
Malaria, Falciparum	low	1
Malignant Neoplasm of Breast	low	4
Malignant Tumor of Breast	low	4
Mammary Cancer	low	4
Mammary Carcinoma, Human	low	4
Mammary Neoplasm, Human	low	4
Mammary Neoplasms, Human	low	4
Maturity-Onset Diabetes	low	1
Maturity-Onset Diabetes Mellitus	low	1
Miscarriage	low	1
MODY	low	1
Myocardial Diseases	low	1
Myocardial Diseases, Primary	low	1
Myocardial Diseases, Secondary	low	1
Myocardiopathies	low	1
Neoplasm Invasion	low	1
Neoplasm Invasiveness	low	1
Neoplasms, Breast	low	4
Neoplasms, Cervical	low	1
Neoplasms, Cervix	low	1
Neoplasms, Endometrial	low	1
Neoplasms, Experimental	low	1
Nervous System Degenerative Diseases	low	1
Neurodegenerative Diseases	low	1
Neurodegenerative Disorders	low	1
Neurologic Degenerative Conditions	low	1
Neurologic Degenerative Diseases	low	1
Neurologic Diseases, Degenerative	low	1
NIDDM	low	1
Noninsulin-Dependent Diabetes Mellitus	low	1
Obesity in Adolescence	low	1
Obesity in Childhood	low	1
Pediatric Obesity	low	1
Plasmodium falciparum Malaria	low	1
Polio	low	1
Polio Encephalitis	low	1
Poliomyelitis	low	1
Poliomyelitis Infection	low	1
Poliomyelitis, Acute	low	1
Poliomyelitis, Nonpoliovirus	low	1
Poliomyelitis, Preparalytic	low	1
Pregnancy	low	21
Prenatal Exposure Delayed Effects	low	9
Primary Myocardial Diseases	low	1
Secondary Myocardial Diseases	low	1
Sensitivity, Contact	low	2
Spontaneous Abortion	low	1
Systolic Heart Failure	low	1
Toxic Hepatitis	low	1
Tumors, Breast	low	4
Type 2 Diabetes	low	1
Type 2 Diabetes Mellitus	low	1
Uterine Cervical Cancer	low	1
Uterine Cervical Dysplasia	low	1
Uterine Cervical Neoplasms	low	1
Zika Fever	low	1
Zika Virus Disease	low	1
Zika Virus Infection	low	1
ZikV Infection	low	1

Article	Year
UHPLC-MS/MS Determination, Pharmacokinetic, and Bioavailability Study of Taxifolin in Rat Plasma after Oral Administration of its Nanodispersion. Molecules (Basel, Switzerland), Apr-14, Volume: 21, Issue: 4	2016
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Genotoxic effects in transformed and non-transformed human breast cell lines after exposure to silver nanoparticles in combination with aluminium chloride, butylparaben or di-n-butylphthalate. Toxicology in vitro : an international journal published in association with BIBRA, Volume: 45, Issue: Pt 1	2017
Simultaneous analysis of antioxidants and preservatives in cosmetics by supercritical fluid extraction combined with liquid chromatography-mass spectrometry. Journal of chromatography. A, Jul-07, Volume: 1120, Issue: 1-2	2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

butylparaben

Cross-References

Synonyms (166)

Research Excerpts

Overview

Effects

Actions

Drug Classes (1)

Protein Targets (53)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (264)

Molecular Functions (84)

Ceullar Components (44)

Bioassays (68)

Research

Studies (187)

Study Types

Related Drugs (535)

Related Conditions (197)

Research Highlights

Safety/Toxicity (10)

Pharmacokinetics (1)

Bioavailability (3)

Dosage (14)

Interactions (2)